Genzyme Co-pay Assistance Program

The Genzyme Co-Pay Assistance Program helps eligible individuals in the United States who are prescribed treatment with Cerezyme pay for their eligible out-of-pocket drug related expenses, including co-pays, co-insurance and deductibles, regardless of financial status.

Once enrolled in Genzyme's Co-Pay Assistance Program, Genzyme will cover 100% of your eligible out-of-pocket Cerezyme drug costs up to the program maximum.

The 2012 Co-Pay Program runs from January 1, 2012 through December 31, 2012.

Once approved for assistance, your healthcare provider will be provided with information about your enrollment in this program along with directions on how to submit a claim to the Genzyme Co-Pay Assistance Program.

Who is eligible for the Genzyme Co-Pay Assistance Program?

Regardless of financial status, the program is open to individuals who are:

  • U.S. citizens or legal residents who have primary commercial insurance
  • Prescribed treatment with Cerezyme

You are NOT eligible if:

  • Are a resident of Massachusetts
  • Have coverage or prescriptions paid for in part or full under any state or federally funded healthcare program including:
    • Medicare
    • Medicare Advantage Plans
      (Example: FreedomBlue offered through Blue Cross Blue Shield)
    • Medicaid
    • Medigap
    • Veterans Affairs, Department of Defense or Tri Care
    • High Risk Pool or Pre-existing Condition Insurance Plan (PCIP)

Genzyme reserves the right to make eligibility determinations, to set program benefit maximums, to monitor participation, and to modify or discontinue the program at any time. This program assists patients with their out-of-pocket drug cost of Cerezyme only, not the cost of the infusion, medical evaluations/appointments, testing, or other related services.

How to get started:

STEP 1
You complete the program application

Simply complete the online application available here.

Helpful information to have on hand when you apply:

  • Your treating Physician's contact information
  • Your health insurance card

You can also call your Genzyme Case Manager directly to learn more about the program and application process at 1-800-745-4447, Option 3

STEP 2
Your Genzyme Case Manager verifies eligibility

Your Genzyme Case Manager will review your application to verify eligibility.

If you are eligible, you will be automatically enrolled in the program.

STEP 3
You're enrolled!

Once approved, you will receive confirmation from your Genzyme Case Manager and an enrollment card will be mailed to you within 7-10 days.

Your doctor or specialty pharmacy will also receive a confirmation letter with instructions on how to submit claims for reimbursement through the program.

Your enrollment in the program is effective from the date of approval through the end of 2012.

Your participation in the program is for the current calendar year (Calendar year runs January-December). You will be able to renew enrollment by visiting www.Cerezyme.com to complete the online renewal form, or contact your Genzyme Case Manager directly or call 1-800-745-4447, Option 3.

Indication & Usage

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

  1. anemia (low red blood cell count)
  2. thrombocytopenia (low blood platelet count)
  3. bone disease
  4. hepatomegaly or splenomegaly (enlarged liver or spleen)

Important Safety Information

Approximately 15% of patients have developed immune responses (antibodies). These patients have a higher risk of an allergic reaction (hypersensitivity). Use Cerezyme® (imiglucerase for injection) carefully if you have had an allergic reaction to the product in the past. Symptoms suggestive of allergic reaction happened in 6.6% of patients, and include anaphylactoid reaction (a serious allergic reaction), itching, flushing, hives, an accumulation of fluid under the skin, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure.

Side effects related to Cerezyme administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported side effects include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Because Cerezyme therapy is administered by intravenous infusion, reactions at the site of injection may occur: discomfort, itching, burning, swelling or uninfected abscess. Cerezyme is available by prescription only. For more information, consult your physician.

Please see Full Prescribing Information (PDF).